— Know what they know.
Not Investment Advice

ZBIO NASDAQ

Zenas BioPharma, Inc.
1W: +5.0% 1M: -1.1% 3M: -23.3% YTD: -42.5% 1Y: +72.8%
$18.97
-0.87 (-4.39%)
 
Weekly Expected Move ±11.6%
$14 $16 $18 $20 $23
NASDAQ · Healthcare · Biotechnology · Alpha Radar Neutral · Power 49 · $846.9M mcap · 10M float · 6.72% daily turnover · Short 54% of daily vol

Cash Flow Trends

Operating Cash Flow
-$172M -44.0% ▼
Capital Expenditures
$18K +86.3% ▲
3Y CAGR: -79.8%
Free Cash Flow
-$172M -43.9% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$209M -179.6% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$119M-$37M-$157M-$378M
Depreciation & Amort.$78K$113K$137K-$2M
Stock-Based Comp.$737K$3M$11M$26M
Change in Working Capital$8M-$8M$25M$951K
Other Non-Cash Items$45M$11M$925K$180M
Operating Cash Flow-$66M-$31M-$120M-$172M
— Investing Activities —
Capital Expenditures-$198K-$17K-$131K-$18K
Acquisitions (Net)$0$0$0$0
Investment Purchases$0$0-$36M-$418M
Investment Sales$0$0$6M$201M
Other Investing-$2M$0$0-$35M
Investing Cash Flow-$2M-$17K-$31M-$252M
— Financing Activities —
Net Debt Issuance$0$20M$0$0
Stock Repurchased$0$0$0$0
Dividends Paid$0$0$0$0
Other Financing$0$0-$6M$62M
Financing Cash Flow$59M$20M$413M$215M
Net Change in Cash-$8M-$10M$263M-$209M
Cash End of Period$67M$57M$320M$111M
Free Cash Flow-$68M-$31M-$120M-$172M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms